10628 Science Center Drive
Suite 250
San Diego, CA 92121
United States
858 900 2660
https://arcturusrx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 180
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Joseph E. Payne M.Sc. | Founder, President, CEO & Director | 1.13M | N/A | 1972 |
Dr. Padmanabh Chivukula Ph.D. | Founder, Chief Scientific Officer, COO & Secretary | 787.5k | N/A | 1979 |
Mr. Andrew H. Sassine MBA | CFO & Director | 826.88k | N/A | 1964 |
Ms. Neda Safarzadeh | Vice President and Head of IR/PR & Marketing | N/A | N/A | N/A |
Mr. Lance Kurata | Chief Legal Officer | 560k | N/A | N/A |
Ms. Natash O. Bowman | Chief Human Resources Officer | N/A | N/A | N/A |
Mr. Kevin T. Skol | Chief Business Officer | N/A | N/A | N/A |
Dr. Juergen Froehlich FCPh, M.D., MBA | Chief Medical Officer | N/A | N/A | 1956 |
Dr. Igor Smolenov M.D., Ph.D. | Chief Development Officer | N/A | N/A | N/A |
Joseph Roberts | Controller | N/A | N/A | N/A |
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics Holdings Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 6; Compensation: 10.